Venetoclax for the treatment of chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q47875923

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Venetoclax for the treatment of chronic lymphocytic leukemia.

@en

Venetoclax for the treatment of chronic lymphocytic leukemia.

@nl

type

Item

label

Venetoclax for the treatment of chronic lymphocytic leukemia.

@en

Venetoclax for the treatment of chronic lymphocytic leukemia.

@nl

prefLabel

Venetoclax for the treatment of chronic lymphocytic leukemia.

@en

Venetoclax for the treatment of chronic lymphocytic leukemia.

@nl

P1476

Venetoclax for the treatment of chronic lymphocytic leukemia

@en

P2093

Angela Palummo

http://www.w3.org/2001/XMLSchema#string

Anna Grazia Recchia

http://www.w3.org/2001/XMLSchema#string

Annamaria Petrungaro

http://www.w3.org/2001/XMLSchema#string

Ernesto Vigna

http://www.w3.org/2001/XMLSchema#string

Fortunato Morabito

http://www.w3.org/2001/XMLSchema#string

Francesca Storino

http://www.w3.org/2001/XMLSchema#string

Giuseppina Uccello

http://www.w3.org/2001/XMLSchema#string

Laura De Stefano

http://www.w3.org/2001/XMLSchema#string

Massimo Gentile

http://www.w3.org/2001/XMLSchema#string

Nadia Caruso

http://www.w3.org/2001/XMLSchema#string

P2860

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.

Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base.

Programmed anuclear cell death delimits platelet life span.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

P304

1307-1316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1386173

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Martino

P577

2017-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28972395

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

lymphocyte